Interferon beta antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-12448439-B2
Application number	US-202318511744-A
Country	US
Kind code	B2
Filing date	Nov 16, 2023
Priority date	Apr 29, 2016
Publication date	Oct 21, 2025
Grant date	Oct 21, 2025

Abstract

The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFNβ). Such antibodies, or antigen-binding fragments thereof, are are useful for various therapeutic or diagnostic purposes.

First claim

What is claimed is:

1. A method of treating a disease, disorder, or condition, in which increased activity of IFNβ is pathogenic, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of the antibody, or antigen-binding fragment thereof, that specifically binds human IFNβ, wherein the antibody or antigen-binding fragment comprises (a) the CDR-H1, CDR-H2, and CDR-H3 sequences of SEQ ID NO: 28, and (b)
i) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 2;
ii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 3;
iii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 4;
iv) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 5;
v) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 6;
vi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 7;
vii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 8;
viii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 9;
ix) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 10;
x) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 11;
xi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 12;
xii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 13;
xiii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 14;
xiv) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 15;
xv) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 16;
xvi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 17;
xvii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 18;
xviii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 19;
xix) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 20;
xx) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 21;
xxi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 22;
xxii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 23;
xxiii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 24;
xxiv) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 25;
XXV) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 26;
xxvi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 27; or
xxvii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 1;
or a pharmaceutical composition comprising the antibody or antigen-binding fragment; wherein the disease, disorder, or condition, in which increased activity of IFNβ is pathogenic, is dermatomyositis (DM).

2. The method according to claim 1 , wherein the antibody or antigen-binding fragment comprises (a) the VH sequence of SEQ ID NO: 28, and (b)
i) the VL sequence of SEQ ID NO: 2;
ii) the VL sequence of SEQ ID NO: 3;
iii) the VL sequence of SEQ ID NO: 4;
iv) the VL sequence of SEQ ID NO: 5;
v) the VL sequence of SEQ ID NO: 6;
vi) the VL sequence of SEQ ID NO: 7;
vii) the VL sequence of SEQ ID NO: 8;
viii) the VL sequence of SEQ ID NO: 9;
ix) the VL sequence of SEQ ID NO: 10;
x) the VL sequence of SEQ ID NO: 11;
xi) the VL sequence of SEQ ID NO: 12;
xii) the VL sequence of SEQ ID NO: 13;
xiii) the VL sequence of SEQ ID NO: 14;
xiv) the VL sequence of SEQ ID NO: 15;
XV) the VL sequence of SEQ ID NO: 16;
xvi) the VL sequence of SEQ ID NO: 17;
xvii) the VL sequence of SEQ ID NO: 18;
xviii) the VL sequence of SEQ ID NO: 19;
xix) the VL sequence of SEQ ID NO: 20;
xx) the VL sequence of SEQ ID NO: 21;
xxi) the VL sequence of SEQ ID NO: 22;
xxii) the VL sequence of SEQ ID NO: 23;
xxiii) the VL sequence of SEQ ID NO: 24;
xxiv) the VL sequence of SEQ ID NO: 25;
xxv) the VL sequence of SEQ ID NO: 26;
xxvi) the VL sequence of SEQ ID NO: 27; or
xxvii) the VL sequence of SEQ ID NO: 1.

3. The method according to claim 1 , wherein the antibody or antigen-binding fragment thereof comprises:
(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 37;
(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 38;
(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 39;
(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 34;
(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 35; and
(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 36.

4. The method according to claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a VH that comprises the amino acid sequence of SEQ ID NO: 28 and a VL that comprises the amino acid sequence of SEQ ID NO: 1.

5. The method according to claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a heavy chain that comprises the amino acid sequence of SEQ ID NO: 33 and a light chain that comprises the amino acid sequence of SEQ ID NO: 32.

6. The method according to claim 1 , wherein the activity of IFNβ is selected from the group consisting of binding to the type I interferon receptor (IFNAR), increasing expression of an IFNβ-dependent gene, and inducing phosphorylation of STAT1, and/or STAT2.

7. The method according to claim 6 , wherein the activity of IFNβ is binding to IFNAR.

8. The method according to claim 6 , wherein the activity of IFNβ is increasing expression of an IFNβ-dependent gene.

9. The method according to claim 6 , wherein the activity of IFNβ is inducing phosphorylation of STAT1, and/or STAT2.

Assignees

• Pfizer
• Brigham & Womens Hospital Inc

Inventors

• Gulla Stefano V
• Huard Christine
• Buhlmann Janet Elizabeth
• Almagro Juan Carlos
• Kodangattil Sreekumar R
• Greenberg Steven A
• Lavallie Edward Roland
• Bennett Eric M
• Mosyak Lidia
• Hall James Perry
• Coyle Anthony John

Classifications

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/515

  Complete light chain, i.e. VL + CL · CPC title

• C07K2317/51

  Complete heavy chain or Fd fragment, i.e. VH + CH1 · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title